FOI 5067 – PBAC's consideration of Nurtec

This FOI request is for correspondence regarding the Public Summary Documents of the Pharmaceutical Benefits Advisory Committee (PBAC) consideration of Pfizer's Nurtec (rimegepant) since July 2023.

Help us improve health.gov.au

If you would like a response please provide an email address. Your email address is covered by our privacy policy.